News

Adva-27a is an anti-cancer compound which has proven effective at killing multidrug resistant breast cancer cells (MCF-7/MDR) and small-cell lung cancer cells (H69AR). Sunshine president and CEO Steve

The launch was based on the completion of clinical evaluation of EasyCell analyzer at Boston Children’s Hospital, which confirmed the instrument’s efficacy in the hematology laboratory environment. Boston

The randomised, double-blind multi-center Phase III study was conducted in patients with advanced hepatocellular carcinoma (HCC), who have not received prior systemic treatment. Bristol-Myers Squibb global development and

Rebamipide ophthalmic suspension has a new mechanism of action to increase the level of mucin in the tear film covering the conjunctiva and cornea. The drug was launched

PAREXEL enhances development network and will provide access to a range of drug development support services, which are customized to meet the needs of Korean national companies and

BZA/CE is designed for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. The company said BZA/CE

The $102.5m worth contract will help the National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) to develop medical countermeasures against infectious

The integrated oncology data solution will provide promotional spending combined with actual drug usage data across a significant sample of US Oncologists. The technology will allow pharmaceutical marketers

As part of the contract, Clinipace Worldwide will study Proleukin (aldesleukin) and Vemurafenib therapy in patients with metastatic melanoma (mM). The study with a sample size of 135